Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a clinical studies with Z160, a selective N-type calcium channel blocker designed to potentially treat chronic neuropathic pain.
Zalicus (ZLCS +9.5%) trades up today after saying it's initiated the second of two Phase 2a...
From other sites
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagentat CNBC.com (Nov 14, 2013)
at CNBC.com (Nov 11, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs